Federated Hermes’s Biodesix BDSX Stock Holding History

Federated Hermes’s Portfolio BDSX Stock Details BDSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-29	Closed	-$1K	–	2147
2022 Q2	$1K	Buy	29 +21	+263%	+$683	﹤0.01%	2023
2022 Q1	$1K	Buy	+8	New	+$523	﹤0.01%	2066

Other funds holding BDSX

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes's BDSX Position: Q3 2022 in Review

Federated Hermes sold out of Biodesix (BDSX) in Q3 2022, closing a stake of 29 shares — an estimated $1K sold.

Federated Hermes first reported a position in BDSX in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q2 2022. 27 funds tracked by Wall St. Rank hold BDSX as of Q3 2022.

Federated Hermes reported no remaining Biodesix position as of Q3 2022 after selling out during the quarter.
Federated Hermes sold 29 Biodesix shares in Q3 2022, an estimated $1K.
Federated Hermes first reported a position in Biodesix in Q1 2022 and held it in 2 quarters.
Federated Hermes's Biodesix position peaked at $1K in Q2 2022.
27 funds tracked by Wall St. Rank held Biodesix as of Q3 2022.

Based on Federated Hermes's 13F filing for Q3 2022, filed 14 Nov 2022.